Subject ID | scRNA-seq | FACS/RT-PCR | Samples biopsied for scRNA-seq | Age | Sex | Ethnicity | Diagnosis | Large cell transformation | Disease duration (years) | Ongoing treatment | Previous treatments | Disease stage |
---|---|---|---|---|---|---|---|---|---|---|---|---|
MF309 | x | x | Patch and tumor (trunk) | 76 | Male | Caucasian | CD4+ MF, CD30+ | Present | Diagnosis 22 years ago; symptoms reported since age 37 | ECP | Topical GCS, IFN alpha | IVA1 (T3N0M0B2) |
MF309 | x | Â | Ulcerated tumor (follow-up lesion trunk) and nonlesional skin (trunk) | 76 | Â | Â | CD4+ MF, CD30+ | Present | Â | ECP | Brentuximab | IVA1 (T3N0M0B2) |
MF311 | x | x | Patch and plaque (trunk) | 74 | Female | Caucasian | CD4 + MF, CD30- | Absent | Diagnosis 2 years ago; symptoms reported since age 53 | ECP | NB-UVB, bexarotene, PUVA, topical and systemic GCS, IFN alpha, alemtuzumab, local radiotheraphy (x ray) | IVA1 (T2N1M0B2) |
MF311 | x |  | Nonlesional skin (lower extremity) | 74 |  |  | CD4 + MF, CD30- | Absent |  | ECP |  | IVA1 (T2N1M0B2) |
MF311 | x |  | Erythroderma (follow-up lesion upper extremity) | 75 |  |  | CD4 + MF, CD30- | Absent |  | ECP, chlorambucil, systemic GCS |  | IVA1 (T4N1M0B2) |
MF312 | x |  | Patch and plaque (upper extremity) | 55 | Male | Caucasian | CD4 + MF, CD30+ | Present | Diagnosis 6 years ago; symptoms since age 44 | ECP, IFN alpha, acitretin | Topical GCS, NB-UVB, local radiotherapy (x ray) | IIB* (T2bN0M0B0) |
MF312 | x | Â | Cleared (follow-up) lesion (upper extremity) | 56 | Â | Â | Â | n.a. | Â | ECP, chlormethine | Â | IIB* (T1aN0M0B0) |
MF318 | x | Â | Patch and plaque (thigh) | 55 | Female | Caucasian | gamma/delta MF, CD30+ | Absent | Symptoms since age 52; recently diagnosed | none | Topical GCS and CNI, NB-UVB | IIB** (T3N0M0B0) |
P65 | x |  | Patch and non-lesional skin (upper extremity) | 53 | Male | Caucasian | CD4 + MF, CD30- | Absent | Symptoms for > 10 years; recently diagnosed | none | Topical GCS | IB (T2aN0M0B0) |
P107 | x |  | Patch lower back | 39 | Female | Caucasian | CD4−/CD8-MF, CD30+ | Absent | Symptoms for > 20 years; diagnosed at age 37 | none | Topical GCS | IA (T1bN0M0B0) |
P107 |  | x | Plaque lower back | 39 | Female | Caucasian | CD4−/CD8-MF, CD30+ | Absent | Symptoms for > 20 years; diagnosed at age 37 | none | Topical GCS | IA (T1bN0M0B0) |
P138 | x |  | Patch thigh | 47 | Male | Caucasian | CD4 + MF | Absent | Symptoms for > 20 years; recently diagnosed | none | Topical GCS | IA (T1aN0M0B0) |
P73 | x |  | Plaque and non-lesional skin (lower extremity) | 82 | Male | Caucasian | folliculotropic MF, CD30- | Absent | Diagnosis 6 years ago | none | PUVA, topical GCS, Re-PUVA, local radiotherapy | IIB (T3N0M0B0) |
P84 | x |  | Plaque (upper extremity) | 75 | Male | Caucasian | CD4 + MF, CD30- | Absent | Symptoms for 6 months; recently diagnosed | none | NB-UVB, topical GCS | IIB (T3N0M0B1) |
P84 | x | Â | Cleared (follow-up) lesion (upper extremity) | 75 | Â | Â | CD4+ MF, CD30- | Absent | Â | PUVA | Â | IIB (T3N0M0B1) |
P90 | x |  | Patch and non-lesional skin (upper extremity) | 75 | Male | Caucasian | CD4 + MF | Absent | Diagnosis at age 64 | none | topical GCS, PUVA, NB-UVB, bexarotene, acitretin | IB (T2aN0M0B0) |
P15 |  | x | Tumor trunk | 59 | Male | Caucasian | CD4 + MF, CD30+ | Present | Diagnosis at age 56 | Brentuximab vedotin | Topical and systemic GCS | IIB (T3N0M0B0) |
P182 |  | x | Patch and plaque (trunk) | 49 | Female | Caucasian | CD4 + CD8 + MF, CD30+ | Absent | Onset of symptoms 4 months ago, recently diagnosed | none | none | IA (T1bN0M0B1) |
P112 | x | Â | Healthy control skin | 51 | Female | Caucasian | n.a. | n.a. | n.a. | none | n.a. | n.a. |
P115 | x | Â | Healthy control skin | 48 | Male | Caucasian | n.a. | n.a. | n.a. | none | n.a. | n.a. |
P116 | x | Â | Healthy control skin | 57 | Female | Caucasian | n.a. | n.a. | n.a. | none | n.a. | n.a. |
P121 | x | Â | Healthy control skin | 44 | Female | Caucasian | n.a. | n.a. | n.a. | none | n.a. | n.a. |